¼¼°èÀÇ ¼¶¸Á ½ÃÀå
Delirium
»óǰÄÚµå : 1758154
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 281 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,195,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,585,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ¼¶¸Á ½ÃÀåÀº 2030³â±îÁö 4,150¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 3,270¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ ¼¶¸Á ½ÃÀåÀº 2024-2030³â¿¡ CAGR 4.0%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 4,150¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ °úȰµ¿ÇüÀº CAGR 5.0%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 2,460¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀúȰµ¿Çü ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ Áß CAGR 2.6%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 890¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 7.6%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ¼¶¸Á ½ÃÀåÀº 2024³â¿¡ 890¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 850¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀº 7.6%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 1.6%¿Í 3.2%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 2.4%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ¼¶¸Á Ä¡·á ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

¼¶¸ÁÀÌ ±Þ¼º±â ÀÇ·á¿Í ³ëÀÎ ÀÇ·á¿¡¼­ ¿ì¼±¼øÀ§·Î ¶°¿À¸£´Â ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

¼¶¸ÁÀº °©ÀÛ½º·¯¿î Âø¶õ, ¹æÇâ °¨°¢ »ó½Ç, ÀÇ½Ä ¼öÁØÀÇ º¯µ¿À» Ư¡À¸·Î Çϸç, ÀÔ¿ø ȯÀÚ, ƯÈ÷ ³ëÀÎ, ÁßȯÀÚ½Ç È¯ÀÚ, ¼ö¼ú ÈÄ È¯ÀÚ¿¡¼­ ½É°¢ÇÑ ÇÕº´ÁõÀ¸·Î Àνĵǰí ÀÖ½À´Ï´Ù. ±× ¿µÇâÀº °ú¼ÒÆò°¡µÇ´Â °æÇâÀÌ ÀÖÁö¸¸, ¼¶¸ÁÀº ÀÌȯÀ² Áõ°¡, ÀÔ¿ø ±â°£ ¿¬Àå, ÀÇ·áºñ Áõ°¡, Àå±âÀûÀÎ ÀÎÁö ±â´É ÀúÇÏ À§Çè Áõ°¡¿Í °ü·ÃÀÌ ÀÖ½À´Ï´Ù. Àü ¼¼°è Àα¸°¡ °í·ÉÈ­µÇ°í ÀÔ¿øÀ» ÇÊ¿ä·Î ÇÏ´Â ¸¸¼ºÁúȯÀÇ ºÎ´ãÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ÀÇ·á ½Ã½ºÅÛ Àü¹Ý¿¡ °ÉÃÄ ¼¶¸Á ¹ß»ý·üÀÌ ±ÞÁõÇϰí ÀÖ½À´Ï´Ù.

ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õµéÀº ƯÈ÷ ³ëÀÎ º´µ¿, ¼ö¼ú ȸº¹½Ç, ÁßȯÀÚ½Ç µî¿¡¼­ ¼¶¸ÁÀÇ Á¶±â ¹ß°ß°ú ¿¹¹æ¿¡ ÁßÁ¡À» µÎ°í ÀÖ½À´Ï´Ù. ÀÌ º´Å´ ÀϹÝÀûÀ¸·Î °¨¿°, ´Ù¾àÁ¦ º´¿ë, ´ë»ç ºÒ±ÕÇü, Ãë¾àÇÑ È¯ÀÚÀÇ ±Þ°ÝÇÑ È¯°æ º¯È­ µî ¿©·¯ °¡Áö À§Çè ¿äÀο¡ ÀÇÇØ ¹ß»ýÇÕ´Ï´Ù. ¼¶¸ÁÀº ´õ ÀÌ»ó ÀÔ¿øÀÇ ºÒ°¡ÇÇÇÑ ºÎºÐÀÌ ¾Æ´Ï¶ó ¿¹¹æ ¹× Ä¡·á °¡´ÉÇÑ ÁõÈıºÀ¸·Î Àνĵǰí ÀÖÀ¸¸ç, È¿°úÀûÀÎ °ü¸®¸¦ À§ÇØ ¾à¸®ÇÐÀû, ºñ¾à¸®ÇÐÀû, ȯ°æÀû Àü·«À» °áÇÕÇÑ ´ÙÇÐÁ¦Àû ÇÁ·ÎÅäÄÝÀÇ °³¹ßÀÌ ¿ä±¸µÇ°í ÀÖ½À´Ï´Ù.

¼¶¸ÁÀ» º¸´Ù È¿°úÀûÀ¸·Î °¨ÁöÇϱâ À§ÇØ Áø´Ü ¹× ¸ð´ÏÅ͸µ ÅøÀº ¾î¶»°Ô ÁøÈ­Çϰí Àִ°¡?

¼¶¸ÁÀÇ Á¶±â ¹× Á¤È®ÇÑ ¹ß°ßÀº ±× °¡º¯ÀûÀΠƯ¼º°ú Ä¡¸Å ¹× ¿ì¿ïÁõ°úÀÇ Áõ»ó Áߺ¹À¸·Î ÀÎÇØ ¿©ÀüÈ÷ Áß¿äÇÑ °úÁ¦ÀÔ´Ï´Ù. ÀÌ¿¡ Confusion Assessment Method(CAM), Intensive Care delirium Screening Checklist(ICDSC), 4AT ½ºÅ©¸®´× Åø µî Ç¥ÁØÈ­µÈ ½ºÅ©¸®´× ÅøÀÌ °³¹ßµÇ¾î ³Î¸® äÅõǰí ÀÖ½À´Ï´Ù. ³Î¸® äÅõǰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Àåºñ´Â ÇöÀç Æ¯È÷ ÀÀ±Þ½Ç, ¼ö¼ú ȸº¹½Ç, ³ëÀÎ º´µ¿ µîÀÇ ÀÓ»ó ÇÁ·ÎÅäÄÝ¿¡ ÇʼöÀûÀÎ ¿ä¼Ò°¡ µÇ°í ÀÖ½À´Ï´Ù. Áö¼ÓÀûÀΠȯÀÚ ¸ð´ÏÅ͸µ ±â¼úµµ ICU¿¡ ÅëÇÕµÇ¾î ¼¶¸ÁÀÇ ¹ßº´À» ¾Ë¸®´Â ÀÎÁö ±â´ÉÀÇ º¯È­¿Í »ý¸®Àû ½ºÆ®·¹½º ÁöÇ¥¸¦ ÃßÀûÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù.

µðÁöÅÐ Çコ Çõ½ÅÀº Áø´Ü ºÐ¾ß¿¡µµ ÁøÃâÇϰí Àִµ¥, AI¸¦ Ȱ¿ëÇÑ ÀÓ»ó ÆÇ´Ü Áö¿ø ½Ã½ºÅÛÀ̳ª ÀüÀڰǰ­±â·Ï(EHR)°ú ¿¬µ¿µÈ °æ°í ½Ã½ºÅÛÀº ½Ç½Ã°£ ÀÓ»ó µ¥ÀÌÅ͸¦ ±â¹ÝÀ¸·Î °íÀ§Ç豺 ȯÀÚ¸¦ ½Äº°Çϱâ À§ÇØ µµÀԵǰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ç÷§ÆûÀº Åõ¾à °ËÅä, ȯ°æ °³¼±, ¼öºÐ º¸Ãæ Áö¿ø, °¨°¢ ¹æÇâ Àüȯ µî Àû½Ã¿¡ °³ÀÔÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù. ºñÀü¹®°¡ °£º´ÀÎÀ» À§ÇØ ¼³°èµÈ ¸ð¹ÙÀÏ ¾Û°ú ħ´ë ¿· Æò°¡ Åøµµ ÁÖ¸ñ¹Þ°í ÀÖÀ¸¸ç, ÀçÅà ¹× Àå±â¿ä¾ç½Ã¼³¿¡¼­ ¹ß°ßÀ²À» ³ôÀÌ´Â µ¥ µµ¿òÀÌ µÇ°í ÀÖ½À´Ï´Ù.

¼¶¸Á °ü¸®¿¡¼­ ¾î¶² Ä¡·á Àü·«ÀÌ È¿°úÀûÀϱî¿ä?

¼¶¸ÁÀÇ °ü¸®´Â ¿¹¹æ, Á¶±â °³ÀÔ, ±Ùº»ÀûÀÎ À¯¹ß ¿äÀÎÀ» ÃÖ¼ÒÈ­ÇÏ´Â µ¥ ÁßÁ¡À» µÓ´Ï´Ù. ºñ¾à¸®ÇÐÀû ÁßÀç´Â ƯÈ÷ ³ëÀÎÀ̳ª ¼ö¼ú ÈÄ È¯ÀÚ¿¡¼­ ¿¹¹æ°ú Ä¡·á ¸ðµÎ¿¡¼­ °¡Àå Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ¿©±â¿¡´Â ¿À¸®¿£Å×ÀÌ¼Ç Àü·«, ¼ö¸é À§»ý ÇÁ·ÎÅäÄÝ, ¼ÒÀ½ °¨¼Ò, ÅëÁõ °ü¸®, °¨°¢ Â÷´ÜÀ» ÁÙÀ̱â À§ÇÑ ½Ã°¢ ¹× û°¢ º¸Á¶ Àåºñ µîÀÌ Æ÷ÇԵ˴ϴÙ. º´¿ø ³ëÀÎ »ýȰ ÇÁ·Î±×·¥(HELP)°ú °°Àº º¹ÇÕÀû ÄÉ¾î ¸ðµ¨Àº ¼¶¸ÁÀÇ À§Çè ¿äÀÎÀ» ü°èÀûÀ¸·Î ´Ù·ç°í ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±Çϱâ À§ÇØ º´¿ø¿¡¼­ äÅõǰí ÀÖ½À´Ï´Ù.

¾à¸®ÇÐÀû Ä¡·á´Â ÀϹÝÀûÀ¸·Î ½ÉÇÑ ÈïºÐÀ̳ª ŸÀο¡ ´ëÇÑ À§Ç輺ÀÌ ÀÖ´Â °æ¿ì¿¡¸¸ ½ÃÇàµË´Ï´Ù. ÇÒ·ÎÆä¸®µ¹°ú °°Àº Ç×Á¤½Åº´Á¦¹°À̳ª ÄùƼ¾ÆÇÉÀ̳ª ¿Ã¶õÀÚÇɰú °°Àº ºñÁ¤Çü ¾à¹°ÀÌ »ç¿ëµÇ±âµµ ÇÏÁö¸¸, ÀÏ»óÀûÀÎ »ç¿ëÀ» ÁöÁöÇÏ´Â Áõ°Å´Â ¾ÆÁ÷ ´Ù¾çÇÕ´Ï´Ù. ¼ö¸é-°¢¼º Áֱ⸦ ¾ÈÁ¤È­½ÃŰ´Â ¸á¶óÅä´ÑÀ̳ª µ¦½º¸Þµ¥Åä¹Ìµò, ÀÎÁö ¼Õ»óÀ» ÃÖ¼ÒÈ­ÇÏ´Â ½Å°æº¸È£Á¦ µî ´ëü ¾à¹°¿ä¹ý¿¡ ´ëÇÑ ¿¬±¸µµ ÁøÇà ÁßÀÔ´Ï´Ù. ±âº»ÀûÀÎ ÀÎÁö »óÅÂ, µ¿¹Ý Áúȯ, ¾à¹° ¹Î°¨µµ¸¦ °í·ÁÇÑ °³º°È­µÈ ÀÇ·á Á¢±ÙÀº ¼¶¸Á Ä¡·á °æ·Î¿¡¼­ Á¡Á¡ ´õ Áß¿äÇØÁö°í ÀÖ½À´Ï´Ù.

¼¶¸Á °ü¸® ½ÃÀå È®´ë¸¦ ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎÀº?

¼¶¸Á °ü¸® ½ÃÀåÀÇ ¼ºÀåÀº Àü ¼¼°è ³ëÀÎ Àα¸ Áõ°¡, ¸¸¼ºÁúȯ ȯÀÚÀÇ ÀÔ¿øÀ² Áõ°¡, ¼¶¸ÁÀÇ À§Çè°ú °á°ú¿¡ ´ëÇÑ ÀÇ·á Àü¹®°¡µéÀÇ ÀÎ½Ä Áõ°¡ µî ¿©·¯ ¿äÀο¡ ±âÀÎÇÕ´Ï´Ù. º´¿øÀÌ ÀçÀÔ¿øÀ², ÁßȯÀÚ½Ç ÇÕº´Áõ, Àå±âÀûÀÎ ÀÎÁö ±â´É Àå¾Ö¸¦ ÁÙÀ̱â À§ÇØ ³ë·ÂÇÏ´Â °¡¿îµ¥, ¼¶¸Á ¿¹¹æ ÇÁ·ÎÅäÄÝÀº Àü¹ÝÀûÀÎ ÀÇ·á Áú °ü¸® ±¸»óÀÇ ÀÏȯÀ¸·Î ¿ì¼±¼øÀ§¸¦ µÎ°í ÀÖ½À´Ï´Ù. ±¹°¡ ÀÇ·á±â°ü ¹× ÀÎÁõ ±â°üÀº ¾ÈÀü ±âÁØ ¹× ¼º°ú ±âÁØÀÇ ÀϺηΠ¼¶¸Á Æò°¡¸¦ Àǹ«È­Çϰí ÀÖ½À´Ï´Ù.

EHR ±â¹Ý ½ºÅ©¸®´× Åø, AI¸¦ Ȱ¿ëÇÑ ÀÓ»óÀû ÆÇ´Ü Áö¿ø, ¿þ¾î·¯ºí ÀÎÁö±â´É ¸ð´ÏÅ͸µ ±â±â´Â ¹ß°ß ¹× °ü¸® ÇÁ·Î¼¼½º¸¦ È¿À²È­ÇÕ´Ï´Ù. ÀÌ¿Í ÇÔ²² ³ëÀκ´ Àü¹®ÀÇ, ½Å°æ°ú Àü¹®ÀÇ, °£È£»ç, ¾à»ç µî ´ÙÇÐÁ¦ Áø·áÆÀÀÇ È®´ë·Î Ä¡·á Á¢±Ù¹ýÀÇ Ç¥ÁØÈ­°¡ °­È­µÇ°í ÀÖ½À´Ï´Ù. ÀçÅà ġ·áÀÇ È°¼ºÈ­¿Í ¼ö¼ú ÈÄ ¶Ç´Â ÁßȯÀÚ½Ç ÀÔ¿ø ÈÄ ¿ø°Ý ¸ð´ÏÅ͸µµµ Áö¿ª ´ÜÀ§ÀÇ ÄÉ¾î ¼Ö·ç¼Ç°úÀÇ ¿¬°ü¼ºÀ» ³ôÀ̰í ÀÖ½À´Ï´Ù. ÀÇ·á ½Ã½ºÅÛÀÌ ½Å°æÀÎÁö ÇÕº´Áõ¿¡ º¸´Ù Àû±ØÀûÀ¸·Î ´ëóÇÔ¿¡ µû¶ó ¼¶¸Á Ä¡·á ¹× ¸ð´ÏÅ͸µ ¿µ¿ªÀº ÀÓ»óÀûÀ¸·Î³ª »ó¾÷ÀûÀ¸·Î³ª Å©°Ô È®´ëµÉ °ÍÀÔ´Ï´Ù.

ºÎ¹®

À¯Çü(°úȰµ¿Çü, ÀúȰµ¿Çü, È¥ÇÕÇü); ÃÖÁ¾ »ç¿ë(º´¿ø ÃÖÁ¾ »ç¿ë, Àü¹®ÀÇ·á ÃÖÁ¾ »ç¿ë, ¿¬±¸ ¼¾ÅÍ ÃÖÁ¾ »ç¿ë)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹

AI ÅëÇÕ

¿ì¸®´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI Åø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾ç ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÔ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Delirium Market to Reach US$41.5 Million by 2030

The global market for Delirium estimated at US$32.7 Million in the year 2024, is expected to reach US$41.5 Million by 2030, growing at a CAGR of 4.0% over the analysis period 2024-2030. Hyperactive Type, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$24.6 Million by the end of the analysis period. Growth in the Hypoactive Type segment is estimated at 2.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$8.9 Million While China is Forecast to Grow at 7.6% CAGR

The Delirium market in the U.S. is estimated at US$8.9 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$8.5 Million by the year 2030 trailing a CAGR of 7.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.6% and 3.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.4% CAGR.

Global Delirium Treatment Market - Key Trends & Drivers Summarized

Why Is Delirium Emerging as a Priority Concern in Acute and Elderly Care?

Delirium, characterized by a sudden onset of confusion, disorientation, and fluctuating levels of consciousness, is increasingly recognized as a serious complication in hospitalized patients-especially among the elderly, ICU patients, and post-operative individuals. Its impact is often underestimated, yet delirium is associated with increased morbidity, prolonged hospital stays, higher healthcare costs, and a greater risk of long-term cognitive decline. As global populations age and the burden of chronic illnesses requiring hospitalization rises, the incidence of delirium is surging across healthcare systems.

Healthcare providers are placing growing emphasis on early identification and prevention of delirium, especially in geriatric wards, surgical recovery units, and intensive care settings. The condition is commonly triggered by multiple risk factors such as infections, polypharmacy, metabolic imbalances, and sudden environmental changes in vulnerable patients. Delirium is no longer viewed as an inevitable part of hospitalization but as a preventable and treatable syndrome, prompting the development of multidisciplinary protocols that combine pharmacological, non-pharmacological, and environmental strategies to manage it effectively.

How Are Diagnostic and Monitoring Tools Evolving to Detect Delirium More Effectively?

Early and accurate detection of delirium remains a critical challenge due to its fluctuating nature and symptom overlap with dementia and depression. This has led to the development and widespread adoption of standardized screening tools such as the Confusion Assessment Method (CAM), the Intensive Care Delirium Screening Checklist (ICDSC), and the 4AT screening tool. These instruments are now integral to clinical protocols, especially in emergency departments, surgical recovery, and geriatric care units. Continuous patient monitoring technologies are also being integrated into ICU settings to track cognitive fluctuations and physiological stress indicators that may signal the onset of delirium.

Digital health innovations are also entering the diagnostic space. AI-powered clinical decision support systems and electronic health record (EHR)-linked alert systems are being deployed to identify high-risk patients based on real-time clinical data. These platforms enable timely interventions such as medication review, environmental modification, hydration support, and sensory reorientation. Mobile apps and bedside assessment tools designed for non-specialist caregivers are also gaining attention, helping improve detection rates in home care and long-term care facilities.

What Therapeutic Strategies Are Gaining Ground in the Management of Delirium?

Management of delirium emphasizes prevention, early intervention, and minimizing underlying triggers. Non-pharmacological interventions remain the gold standard for both prevention and treatment, especially in elderly and post-operative patients. These include orientation strategies, sleep hygiene protocols, noise reduction, pain management, and vision/hearing aids to reduce sensory deprivation. Multicomponent care models such as the Hospital Elder Life Program (HELP) are being adopted by hospitals to systematically address delirium risk factors and improve patient outcomes.

Pharmacological treatments are typically reserved for cases of severe agitation or risk to self and others. Antipsychotics such as haloperidol and atypical agents like quetiapine and olanzapine are sometimes used, although evidence supporting their routine use remains mixed. Research into alternative pharmacotherapies is ongoing, including melatonin and dexmedetomidine for sleep-wake cycle stabilization and neuroprotective agents to minimize cognitive injury. Personalized medicine approaches that account for underlying cognitive status, co-morbidities, and drug sensitivity are becoming increasingly important in delirium care pathways.

What Are the Main Forces Driving the Expansion of the Delirium Management Market?

The growth in the delirium management market is driven by several factors, including the rising global geriatric population, increased hospitalization rates among patients with chronic conditions, and growing awareness among healthcare professionals about the risks and consequences of delirium. As hospitals seek to reduce readmission rates, ICU complications, and long-term cognitive impairment, delirium prevention protocols are being prioritized as part of overall quality care initiatives. National health agencies and accreditation bodies are mandating delirium assessment as part of safety and performance standards.

Technological integration is another growth catalyst, with EHR-based screening tools, AI-enabled clinical decision support, and wearable cognitive monitoring devices streamlining the detection and management process. In parallel, the expansion of multidisciplinary care teams involving geriatricians, neurologists, nurses, and pharmacists is enhancing the standardization of treatment approaches. The push for home-based recovery and remote monitoring post-surgery or ICU stay is also increasing the relevance of community-level delirium care solutions. As healthcare systems become more proactive in addressing neurocognitive complications, the delirium treatment and monitoring landscape is set for significant clinical and commercial expansion

SCOPE OF STUDY:

The report analyzes the Delirium market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Hyperactive Type, Hypoactive Type, Mixed Type); End-Use (Hospitals End-Use, Specialty Care End-Use, Research Centers End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â